Akoya Biosciences Inc   (AKYA)
Other Ticker:  
Price: $5.9800 $-0.05 -0.829%
Day's High: $6.31 Week Perf: 2.4 %
Day's Low: $ 5.88 30 Day Perf: 7.55 %
Volume (M): 182 52 Wk High: $ 12.03
Volume (M$): $ 1,088 52 Wk Avg: $5.75
Open: $6.13 52 Wk Low: $3.04

 Market Capitalization (Millions $) 243
 Shares Outstanding (Millions) 41
 Employees -
 Revenues (TTM) (Millions $) 90
 Net Income (TTM) (Millions $) -71
 Cash Flow (TTM) (Millions $) 27
 Capital Exp. (TTM) (Millions $) 4

Akoya Biosciences Inc
Akoya Biosciences Inc is a company focused on developing and commercializing innovative imaging platforms and reagents for high-content, biomarker analysis in tissue samples. Their technologies enable researchers and clinicians to gain deeper insights and understanding of cellular interactions, tissue structure, and spatial distribution of biomarkers in biological samples. Akoya's flagship product, the CODEX system, combines multiplexed imaging with computational analysis to provide high-resolution spatial information in tissue samples. Their solutions are used in various fields including oncology, neuroscience, immunology, and infectious diseases. Akoya Biosciences Inc aims to accelerate drug discovery, biomarker identification, and refine diagnostics by providing researchers with advanced imaging tools.

   Company Address: 100 Campus Drive Marlborough 1752 MA
   Company Phone Number: 896-8401   Stock Exchange / Ticker: NASDAQ AKYA


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Clinical Study

MaxFuse: Transforming Biomedical Research and Fuelling Revenue Growth - Akoya Biosciences Leads the Way

Published Sun, Jan 7 2024 1:00 PM UTC

In a groundbreaking development, Akoya Biosciences Inc. has successfully deployed the MaxFuse algorithm, co-developed by Dr. Garry Nolan and his laboratory at Stanford University. This algorithm enables the integration of datasets from various biomedical modalities, including spatial proteomics, spatial transcriptomics, single-cell sequencing, and more. Referred to as the En...

Akoya Biosciences Inc

Akoya Biosciences Inc Sees Boost in Revenue but Fails to Reach Profitability in Financial Third Quarter of 2023

Akoya Biosciences Inc (AKYA) has seen a promising surge in its stock price over the past few trading days, with a solid gain of 5.53%. This positive momentum follows an impressive improvement of 15.9% in the preceding 30 days. Furthermore, AKYA stock is currently trading 31.9% above its 52-week low, indicating a strong market position for the company.
The recent financial results of Akoya Biosciences Inc shed some light on the factors driving this upward trajectory. The company's Spatial Biology 2.0 solutions have enabled discovery and translational workflows at an unprecedented speed and scale. This indicates the value and growth potential of Akoya's innovative product offerings.

Akoya Biosciences Inc

Surprising Surge in Revenue for Akoya Biosciences Inc with a Whopping 29.183% Increase during April to June 2023

Akoya Biosciences Inc, a Laboratory Analytical Instruments company, announced a significant surge in revenue during the most recent fiscal period. Compared to the corresponding quarter last year, the company's revenue grew by 29.183% to $23.12 million. However, it also reported an increased loss per share at $-0.51 per share.
This performance by Akoya Biosciences Inc has come as a new revelation to many, as the average revenue for the Laboratory Analytical Instruments industry has decreased by -4.48%. In comparison to the preceding period, the company experienced a surge in loss from $-0.49 per share and a revenue increase of 7.968% from $21.41 million.

Akoya Biosciences Inc

Akoya Biosciences Inc.'s Revenue Surge Fails to Yield Profitability in First Quarter of 2023 Earnings Season

The recent financial report of AKYA raises concerns for investors as the company announces a surge in revenue by 26.731% to $21.41 million from the first quarter of 2022, but with expanding Diminishing Returns at $-0.49 per share. The company has failed to generate any substantial returns for its investors, as the value per share has declined substantially in the past year.
Despite the revenue surge, it is evident that the company is struggling to maintain profitability. The net loss of $-18.802 million in the first quarter of 2023 is a major concern for investors, especially when compared to last year's net loss of $-16.399 million. The company has failed to address the issue of operating losses, and the widening losses continue to raise concerns among investors.


Akoya Biosciences Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com